Ontology highlight
ABSTRACT:
INSTRUMENT(S):
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): Malignant Cell
DISEASE(S): Melanoma
SUBMITTER:
Susana Bravo
LAB HEAD: Susana B Bravo López
PROVIDER: PXD053555 | Pride | 2026-02-09
REPOSITORIES: Pride
| Action | DRS | |||
|---|---|---|---|---|
| A375_C_1.wiff | Wiff | |||
| A375_C_1.wiff.scan | Wiff | |||
| A375_C_1_FDR.xlsx | Xlsx | |||
| A375_C_2.wiff | Wiff | |||
| A375_C_2.wiff.scan | Wiff |
Items per page: 5 1 - 5 of 19 |

Varela-Vázquez Adrián A Guitián-Caamaño Amanda A Carpintero-Fernández Paula P Carneiro-Figueira Alexander A Álvarez Vanesa V Varela-Eirín Marta M Calleja-Chuclá Teresa T Bravo-López Susana B SB Vidal Anxo A Sendón-Lago Juan J Mateos Marina Rodriguez-Candela MR Caeiro José R JR Sanz-Moreno Victoria V Aasen Trond T Blanco Miguel G MG Sabio Guadalupe G Quindós María M Rivas Carmen C Santamaría David D Fernandez-Lozano Carlos C Fonseca Eduardo E Huertas Pablo P Sánchez-Laorden Berta B Alabert Constance C Mayán María D MD
Nature communications 20250704 1
BRAF and MEK inhibitors (BRAF/MEKi) have radically changed the treatment landscape of advanced BRAF mutation-positive tumours. However, limited efficacy and emergence of drug resistance are major barriers for successful treatments. Here, by using relevant preclinical models, we find that Connexin43 (Cx43), a protein that plays a role in cell-to-cell communication, enhances the effectiveness of BRAF/MEKi by recruiting DNA repair complexes to lamin-associated domains and promoting persistent DNA d ...[more]